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Endometrial cancer (EC) is the second most common malignancy associated with hereditary non-polyposis colorectal cancer 
(HNPCC) family. The development of HNPCC is associated with defects in DNA mismatch repair (MMR) pathway resulting 
in microsatellite instability (MSI). MSI is present in a greater number of EC than can be accounted for by inherited MMR muta-
tions, therefore alternative mechanisms may underline defective MMR in EC, including polymorphic variation. Aim: We checked 
the association between EC occurrence and two polymorphisms of MMR genes: a 1032G>A (rs4987188) transition 
in the hMSH2 gene resulting in a Gly22Asp substitution and a –93G>A (rs1800734) transition in the promoter of the hMLH1 gene. 
Material and methods: These polymorphisms were genotyped in DNA from peripheral blood lymphocytes of 100 EC patients and 
100 age-matched women by restriction fragment length polymorphism PCR. Results: A positive association (OR 4.18; 95% 
CI 2.23–7.84) was found for the G/A genotype of the –93G>A polymorphism of the hMLH1 gene and EC occurrence. On the ot-
her hand, the A allele of this polymorphism was associated with decreased EC occurrence. The Gly/Gly genotype slightly increased 
the effect of the –93G>A-G/A genotype (OR 4.52; CI 2.41–8.49). Our results suggest that the –93G>A polymorphism 
of the hMLH1 gene singly and in combination with the Gly322Asp polymorphism of the hMSH2 gene may increase the risk of EC.
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Endometrial cancer (EC) is the most common gy-
necologic malignancy among women in the Europe, 
Asia and North America [1, 2]. As with all solid tumors, 
it is a heterogeneous disease underlined by combina-
tion of genetic and environmental influences. Factors 
involved in the etiology of endometrial malignancy are 
obesity, hypertension, diabetes and hormonal ele-
ments. Family history may also be a risk factor as familial 
clustering of EC has been reported [3]. These cases 
are associated with colon cancer as a part of hereditary 
non-polyposis colorectal cancer (HNPCC) family [4]. 
EC is the second most common cancer associated with 
HNPCC [5, 6]. A part of ECs shares many of the molecu-
lar characteristics of HNPCC, including DNA mismatch 
repair (MMR) deregulation associated with mutations 
in MMR genes [7–9]. These high-penetrance, he-
reditary mutations are linked with the development 
of approximate 10% of all EC [10]. More commonly 
occurring, low-penetrance variant alleles may influence 
susceptibility to sporadic carcinogenesis through their 
effects on protein function and expression [11]. Single 
nucleotide polymorphisms (SNPs) that affect cancer 
transformation may be particularly relevant [12]. A num-
ber of pathways are involved in the EC deve lopment, 
including DNA damage repair, carcinogen metabolism, 
steroid metabolism, and steroid receptor activation 
pathways. Polymorphisms in MMR genes are consi-
dered to be candidate risk factors, because of the cru-
cial role played by these genes in the maintenance 
of genomic integrity. The loss or serious alterations 
in MMR pathway may result in microsatellite instability 
(MSI), a feature occurring in a subset of ECs.  However, 
this subset is larger than that expected from the num-
ber of high-penetrance mutations in MMR genes, 
which implies the involvement of other mechanism(s) 
of EC transformation [6]. Mutations in low-penetrance 
genes, sometimes having a form of polymorphisms, 
may underline EC, since cancer transformation 
is a multi-gene process andcombined effect of even 
small changes in these genes may affect it.
In the present work, we searched for an as-
sociation between EC occurrence and 2 polymor-
phisms of MMR genes: a 1032G>A transition 
in the MSH2 gene, re sulting in a Gly322Asp substi-
tution (the Gly322Asp polymorphism, rs4987188) 
and a –93G>A transit ion in the MLH1 gene 
(the –93G>A polymorphism, rs1800734). We have 
recently correlated the Gly322Asp polymorphism 
with breast cancer [13]. The –93G>A polymorphism, 
due to its location in the core promoter may influence 
the level of transcription of the MLH1 gene. An asso-
ciation of this polymorphism with malignant phenotype 
for colon and lung cancers has been shown [14, 15].
MATERIALS AND METHODS
Patients. Blood was obtained from 100 women 
(median age 48 years) with EC treated in 2010–
2012 in the Polish Mother’s Memorial Hospital (Lodz, 
Poland). All patients had histologically confirmed 
endometrial carcinoma and agreed to complete a risk 
factor questionnaire. The characteristics of the pa-
tients and controls is presented in Table 1. Control 
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samples consisted of DNA extracted from blood cells 
from age-matched 100 cancer-free women. The study 
was approved by the Local Bioethical Committee and 
each patient gave a written consent.
Table 1. Characteristics of EC patients and controls enrolled in the study
Characteristics Cases (n = 100) Controls (n = 100)
Age, years
Mean
Min
Max
61
43
83
55
45
84
Education
Elementary school
Secondary technical school
High school
More than high school
23
17
38
22
22
15
43
20
No. of birds
0
1
> 1
16
30
54
17
32
51
Body mass index
< 19
19–25
26–29
> 30
0
27
41
32
0
33
38
29
First menarche
Before 11 years
12–13 years
14–15 years
After 16 years
Missing
5
35
43
9
8
10
42
30
11
7
Hypertension 51 43
Hormone replacement therapy
Yes
No
Missing
19
81
0
31
60
9
Smoking
No
Past or Current
Missing
64
26
10
62
33
5
Alcohol consumption
Yes
No
Missing
49
49
2
46
48
6
Family cancer
Yes
No
Missing
29
63
8
12
77
11
FIGO stage
I
II
III
IV
71
14
13
2
—
—
—
—
FIGO grade
G1
G2
G3
45
30
25
—
—
—
Genotype determination. Genomic DNA was 
prepared using GeneMatrix Blood DNA purification Kit 
(EURx, Gdansk, Poland) according to the manufac-
turer instruction. Genotypes were determined by re-
striction fragment length polymorphism polymerase 
chain reaction (RFLP-PCR). The following primers 
were used for the Gly322Asp polymorphism — for-
ward: 5’ GTTTTCACTAATGAGCTTGC-3’ and reverse: 
5’-AGTGGTATAATCATGTGGGT -3’; for the –93G>A poly-
morphism — forward: 5’-CTCGTCGAGCCGAATAA-3’ 
and reverse: 5’ AGTAGCCGCTTCAGGGA-3’. The PCR 
reaction was run with a mixture containing 100 ng ge-
nomic DNA, 5 mM dNTPs, 5 pmol each primer and 
1U (in 25 μl) Taq DNA polymerase (Biotools, Madrid, 
Spain) which was added into PCR buffer containing 
10 mMTris-HCl, 1.5 mM MgCl2 and 50 mM KCl. PCR 
conditions were as follows: initial denaturation step 
at 95 °C for 5 min, 30 cycles at 95 °C for 30 s and 
30 s at the 62 °C annealing temperature, and at 72 °C for 
30 s. The final extension step was performed at 72 °C for 
5 min. The PCR was carried out in a MJ Research, INC 
thermal cycler, model PTC-100 (Waltham, MA, USA). 
Aliquots of 20 μl were taken and subjected to restric-
tion digestion with HinfI (the Gly322Arg polymorphism) 
or PvuII (the –93G>A polymorphism, both restriction 
enzymes were from Fermentas, Vilnius, Lithuania). 
The digested products were resolved on an 8% poly-
acrylamide (the Gly322Arg polymorphism) or 2% aga-
rose gel (the –93G>A polymorphism) and stained 
with 0.5 mg/ml ethidium bromide. The cleavage 
of the hMSH2 polymorphic site with HinfI produced 
bands of 252, 252/182/70 and 182/70 bp corre-
sponding to the Gly/Gly, Gly/Asp and Asp/Asp geno-
types, respectively. The PvuII restriction enzyme acting 
on the promoter region of hMLH1 produced bands 
of 259, 259/134/125 and 134/125 bp corresponding 
to the G/G, G/A and A/A genotypes, respectively at –93.
Data analysis. Genotype frequencies were 
tested for Hardy — Weinberg equilibrium using 
the χ2 test. The association between genotype and 
the risk of EC was estimated by odds ratios (OR) and 
95% confidence intervals (95% CI), calculated by un-
conditional logistic regression models. All statistical 
analyses were performed with Statistica (Statsoft, 
Tulusa, OK, USA).
RESULTS
Genotyping was successfully performed for all 
samples in the study. Allele and genotype frequencies 
among the patients and controls were in the Hardy — 
Weinberg equilibrium. No substantial differences 
in environmental risk factors (see Table 1) between 
EC patients and controls were observed. A strong 
association (OR 4.18; 95% CI 2.23–7.84) was found 
between the G/A genotype of the –93G>A polymor-
phism and EC occurrence (Table 2). On the other 
hand, the A allele of this polymorphism was associated 
with decrease in EC occurrence. There were no diffe-
rences in the genotype distributions between cancer 
patients and controls for the Gly322Asp polymorphism 
(Table 3), but the Gly/Gly genotype enhanced a posi-
tive effect of the G/A genotype of the –93G>A poly-
morphism (Table 4).
Table 2. The allele and genotype frequency and OR of the –93G>A poly-
morphism of the hMLH1 gene in EC
Genotype 
or Allele
Patients (n = 100) Controls (n = 100) OR (95% CI)Number Frequency Number Frequency
G/G 18 0.18 9 0.09 2.16 (0.93–4.99)
G/A 81 0.81 50 0.50 4.18* (2.23–7.84)
A/A 1 0.01 41 0.41 0.02 (0.004–0.11)
G 117 0.59 68 0.31 2.71* (1.81–4.08)
A 83 0.41 132 0.69 0.36 (0.24–0.55)
*ORs values with p < 0.001.
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Table 3. The allele and genotype frequencies and OR of the Gly322Asp 
polymorphism of the hMSH2 gene
Genotype 
or Allele
Patients (n = 100) Controls (n = 100) OR (95% CI)Number Frequency Number Frequency
Gly/Gly 98 0.98 96 0.96 1.84 (0.38–8.84)
Gly/Asp 2 0.02 4 0.04 0.54 (0.11–2.62)
Asp/Asp 0 − 0 − −
Met 198 0.98 196 0.96 1.82 (0.38–8.64)
Thr 2 0.02 4 0.04 0.55 (0.11–2.61)
“—” not estimated.
Table 4. The distribution of combined genotypes of the Gly322Asp poly-
morphism of the hMSH2 gene and the –93G>A polymorphism of the 
hMLH1 gene in EC
Genotype 
or Allele
Patients 
(n = 100) Controls (n = 100) OR (95% CI)
Number Fre-quency Number Frequency
Gly/Gly – G/G 17 0.17 8 0.08 2.28 (0.95–5.45)
Gly/Gly — G/A 81 0.81 48 0.48 4.52* (2.41–8.49)
Gly/Gly — A/A 0 − 40 0.40 −
Gly/Asp — G/G 1 0.01 1 0.01 1.00 (0.10–9.78)
Gly/Asp — G/A 1 0.01 2 0.02 0.59 (0.08–4.58)
Gly/Asp — A/A 0 − 1 0.01 −
Asp/Asp — G/G 0 − 0 − −
Asp/Asp — G/A 0 − 0 − −
Asp/Asp — A/A 0 − 0 − −
*OR value with p < 0.001.
DISCUSSION
The main function of the MMR system is to correct 
mismatches left by DNA polymerase during DNA rep-
lication. MMR is also responsible for removal of DNA 
lesions (particularly small DNA loops) formed in ho-
mologous recombination (reviewed in [16]). To date, six 
DNA MMR genes have been identified in human hMLH1, 
hMSH2, hPMS1, hPMS2, hMLH6, and hMSH3. Except 
hMSH3, all remaining MMR genes have been linked 
to HNPCC susceptibility [17–19]. MMR is initiated by the 
heterodimeric complexes hMSH2-hMSH6 (hMutSα) 
and hMSH2-hMSH3 (hMutSβ). Base-base mismatches 
and small loops with up to eight unpaired nucleotides 
are recognized by MutSα. hMutSβ mediates the repair 
of small loops with 2–8 unpaired nucleotides. The 
hMLH1, hPMS1 and hPMS2 form a protein complexes 
that interact with MutSα or hMutSβ. The results obtained 
in the present work suggest that the −93G>A polymor-
phism of the hMLH1 gene singly and in combination with 
the Gly322Asp polymorphism of the hMSH2 gene may 
increase the risk of EC. The role of the −93G>A poly-
morphism in cancer development, if any, has not been 
clarified. The hMLH1 –93A variant has previously 
been associated with an increased risk of develop-
ing hyperplastic colonic polyps in smo kers [20], and 
colorectal cancers [21], particularly in persons with 
a family history of this disease [14]. It was also associ-
ated with risk for squamous cell lung cancers [15]. 
Using immunoche mistry methods, an association 
between the hMLH1 –93A variant and somatic loss 
of hMLH1 protein in MMR deficient colorectal cancer 
was shown [22]. The molecular mechanism which 
lead to disturbance of hMLH1 protein level in the –93A 
variant carriers of the –93G>A polymorphism remains 
unknown. The A allele of this polymorphism did not 
change the level of expression of the gene in luciferase 
assay [23]. It was hypothesized that the –93 variant 
promoted hypermethylation of the promoter sequence 
of the hMLH1 gene, and in this manner disturbed its 
expression. A similar relationship between gene vari-
ant and silencing carrier gene by promoter methylation 
in cancer cells was observed for MGMT gene encoding 
O-6 methylguanine-DNA methyltransferase in colorectal 
cancer [24]. Another large cohort study showed that 
the –93G>A polymorphism of hMLH1 gene was asso-
ciated with hMLH1 promoter methylation and silencing 
the gene, but additional unknown genetic factors con-
tributed also in this process [21]. Indeed, –93G>A is lo-
cated in the promoter region of hMLH1 binding an un-
known factor that is required for the optimal expres-
sion [25]. It is not known whether variation at –93 has 
direct or indirect effect on methylation of the promoter 
region, but it looks that this effect is very strong, what 
was confirmed by the association of the –93A allele 
for both AA homozygotes and AG heterozygotes. This 
might be explained by a dominant trans effects similar 
to transactivation seen in yeast [26]. In a multicenter, 
large cohorts study it was shown that this polymorphism 
was not associated with EC occurrence in Polish and 
British populations [27]. However, it was positively cor-
related with the risk of EC in a large Canadian (Ontario) 
population [28].
We consider  that  the Gly/Gly  genotype 
of the Gly322Asp polymorphism of the hMSH2 gene could 
be one of these factors that enhance observed effect of the 
–93G>A polymorphism of hMLH1 on EC occurrence. 
A large study population showed that the Gly322Asp 
mutation was detected in 2 out of 19 patients with he-
reditary EC [29]. In our work we showed that the EC oc-
currence slightly increased in subjects with –93 A and 
Gly322Gly genotypes carriers (ORs 4.18–4.52).
In summary, our results suggest that the –93G>A poly-
morphism of the hMLH1gene can be associated with 
the occurrence of EC and the Gly322Asp polymorphism 
of the hMSH2 gene increased the risk of EC in individu-
als with the –93A allele. Therefore, genetic variations 
in the DNA MMR system may play a role in the patho-
genesis of EC.
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